Medtronic and Cosmo Pharmaceuticals forge ahead in AI-driven care.

Medtronic plc, a global leader in healthcare technology, has entered into a definitive agreement to expand its partnership with Cosmo Intelligent Medical Devices, a subsidiary of Cosmo Pharmaceuticals. This partnership aims to further capitalize on the achievements of the GI Genius intelligent endoscopy module, which uses AI technology to improve patient outcomes. The collaboration will focus on innovative and scalable AI platforms, such as AI Access, to streamline the development process of medical AI applications. The GI Genius module, powered by AI, has already made a significant impact in gastrointestinal screening by increasing the adenoma detection rate for gastroenterologists. Under the agreement, Medtronic will pay Cosmo $100 million upfront, as well as royalties and milestone payments. [Extracted from the article]